Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Breast Cancer Research and Treatment

Volumn 116, Issue 2, 2009, Pages 263-271

  Jansen, Maurice P H M ^a,b   Ruigrok Ritstier, Kirsten ^a,c   Dorssers, Lambert C J ^a   Van Staveren, Iris L ^a   Look, Maxime P ^a   Meijer Van Gelder, Marion E ^a   Sieuwerts, Anieta M ^a   Helleman, Jozien ^a   Sleijfer, Stefan ^a   Klijn, Jan G M ^a   Foekens, John A ^a   Berns, Els M J J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b LYGATURE   (Netherlands)

^c Netherlands Genomics Center   (Netherlands)

Author keywords

Breast tumors; Endocrine therapy resistance; SIAH2; SiRNA; Ubiquitin E3 ligase

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SEVEN IN ABSENTIA HOMOLOG 2 UBIQUITIN PROTEIN LIGASE E3; TAMOXIFEN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 67649159920     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0125-z     Document Type: Article

References (26)

1. Chung YL, Sheu ML, Yang SC et al (2002) Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97:306-312. doi:10.1002/ijc.1614
2. Jansen MP, Foekens JA, van Staveren IL et al (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740. doi:10.1200/ JCO.2005.05.145
3. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752. doi:10.1038/ 35021093
4. van't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536. doi:10.1038/415530a
5. Roh MS, Hong SH, Jeong JS et al (2004) Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci 19:275-282
6. Kulakosky PC, McCarty MA, Jernigan SC et al (2002) Response element sequence modulates estrogen receptor alpha and beta affinity and activity. J Mol Endocrinol 29:137-152. doi: 10.1677/jme.0.0290137
7. Holloway AJ, Della NG, Fletcher CF et al (1997) Chromosomal mapping of five highly conserved murine homologues of the Drosophila RING finger gene seven-in-absentia. Genomics 41:160-168. doi:10.1006/geno.1997.4642
8. Hu G, Chung YL, Glover T et al (1997) Characterization of human homologs of the Drosophila seven in absentia (sina) gene. Genomics 46:103-111. doi:10.1006/geno.1997.4997
9. Frasor J, Danes JM, Funk CC, Katzenellenbogen BS (2005) Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci USA 102:13153-13157. doi: 10.1073/pnas.0502782102
10. Perissi V, Aggarwal A, Glass CK et al (2004) A corepressor/ coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116:511-526. doi:10.1016/S0092-8674(04)00133-3
11. Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19:1543-1554. doi:10.1210/me.2004-0395
12. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
13. Wang LH, Yang XY, Zhang X et al (2006) Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10:487-499. doi:10.1016/j.ccr.2006.09.015
14. Jansen MP, Sieuwerts AM, Look MP et al (2007) HOXB13-to- IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 25:662-668. doi:10.1200/JCO.2006.07.3676
15. McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235. doi: 10.1007/s10549-006-9242-8
16. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M et al (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11:7311-7321. doi:10.1158/1078-0432.CCR-05-0560
17. Dorssers LC, van Agthoven T, Brinkman A et al (2005) Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res 7:R82-R92. doi: 10.1186/bcr954
18. Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414
19. Foekens JA, Schmitt M, van Putten WL et al (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658
20. Creighton CJ, Hilger AM, Murthy S et al (2006) Activation of mitogen-activated protein kinase in estrogen receptor alphapositive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66:3903-3911. doi:10.1158/0008-5472. CAN-05-4363
21. Frasor J, Stossi F, Danes JM et al (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533. doi:10.1158/0008-5472. CAN-03-3326
22. Massarweh S, Osborne CK, Creighton CJ et al (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833. doi:10.1158/0008-5472. CAN-07-2707
23. Dowsett M, Nicholson RI, Pietras RJ (2005) Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93:S11-S18. doi: 10.1007/s10549-005-9037-3
24. Schiff R, Massarweh SA, Shou J et al (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-336S. doi:10.1158/1078-0432.CCR- 031212
25. Guix M, Granja Nde M, Meszoely I et al (2008) Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897-
26. doi:10.1200/JCO.2007.13.5939